Kininogenase activity was detected by cleavage of radiolabeled substrate (1251-high molecular weight kininogen IHMWKI) in 22 of 24 bronchoalveolar lavage (BAL) fluid samples from 17 asthmatics who either responded to aerosolized allergen challenge or had symptoms of active asthma. In contrast, six of seven normal controls lacked enzymatic activity. Levels of free immunoreactive kinin found in BAL fluid correlated with the presence of kininogenase activity (P = 0.002). The cleavage pattern of 1251-HMWK by the BAL fluid kininogenase (a dominant 65,000-mol wt fragment), and synthetic inhibitor profile (phephe-arg-CH2Cl and phenylmethylsulfonyl fluoride) were compatible with a tissue kallikrein. Peak kininogenase activity eluted at an apparent molecular weight of 20,000-34,000 by HPLC gel filtration. Its antigenic identity was established by immunoblotting with anti-human urinary kallikrein antibody and its activity was inhibited by this antibody. Lysylbradykinin was generated during incubation offractionated BAL fluid and purified HMWK, the characteristic cleavage product of the tissue kallikreins. We conclude that elevated amounts of tissue kallikrein and kinin are present in the bronchoalveolar spaces of asthmatic subjects. Kinin generation may contribute to the asthmatic response directly through edema formation and smooth muscle contraction and by augmenting release and/or production of preformed (histamine) and secondary mediators such as leukotrienes and platelet-activating factor.
Introduction
The inherent edema-promoting and smooth muscle-contracting properties of kinin suggest that kinin-generating systems may participate in the pathogenesis of asthma. Inhalational studies have corroborated the ability of bradykinin to provoke bronchospasm in human asthmatics but not in normal individuals (1) (2) (3) , consistent with the exaggerated bronchial hyperreactivity that typifies the asthmatic group (4) .
Kinins may additionally serve to amplify the release and/or production of other putative mediators in asthma. These could theoretically include the preformed mast cell product histamine, and generation of lipid-derived substances (arachidonate metabolites and platelet-activating factor). Ishizaka et al. (5) showed that bradykinin could substitute for glycosylation-enhancing This is Publication No. 4000IMM from the Department ofImmunology of the Scripps Clinic and Research Foundation.
Receivedfor publication I October 1985 and in revisedform 29August 1986. factor (GEF)' in releasing histamine and arachidonate from cultured murine mast cells (5) . the addition of bradykinin or GEF resulted in phospholipid methylation, increased in cAMP levels, and Ca2+ influx, identical to the changes observed after bridging of IgE receptors. In additional investigations on tissue cell lines, animal organ explants, and human platelets, kinins have been shown to increase arachidonic acid release and metabolism, (including 5-lipoxygenase products), most likely via stimulation of phospholipase A2 and phospholipase C (6) (7) (8) (9) . Increased production of platelet-activating factor after kinin stimulation has also been demonstrated using cultured human endothelial cells (10) .
Direct evidence linking kinin generation to local inflammatory reactions was first provided by Proud et al. (1 1) who used an in vivo nasal lavage system (11) . These investigators demonstrated that nasal installation of allergen in atopic individuals elevated the concentration of kinins in lavage fluid, correlating with symptoms, p-tosyl-L-arginine methyl ester (TAME) esterase activity, and histamine release. Provocation by cold, dry air (12) and symptomatic rhinovirus infection (13) have also been shown to result in increased nasal lavage kinin concentrations. The nasal model may be analagous to asthma, where, in susceptable individuals, diverse stimuli may provoke the bronchoconstriction, augmented mucous production, and leukocyte influx that are hallmarks of the disease (14).
We now provide evidence that the bronchoalveolar lavage (BAL) fluid of asthmatic subjects contains kinin-generating activity. The focus ofthis report is the initial description ofa tissue kallikrein, the predominant kininogenase in these individuals. The presence of plasma kallikrein was also identified in a minority of subjects.
Methods

Study population ASTHMATICS
All subjects fulfilled criteria of the American Thoracic Society for the diagnosis ofasthma (16). Clinical histories were compatible with reversible airways disease. A .20% immediate reversible component (forced expiratory volume [FEY,] ) to B2 agonist inhalation or provocative challenge (allergen or methacholine inhalation) was established. Age of the subjects ranged from 19 to 71 yr. 18 asthmatic subjects were studied and classified into one of two groups:
Challenged asthmatics. Seven volunteer subjects were studied after positive responses to aerosolized allergen inhalation challenge. All were nonsmokers with positive cutaneous reactions to allergen extracts (whealflare reaction at .1:100 wt/vol dilution by intradermal testings), and with suggestive histories of allergen-provoked bronchospasm. All had stable baseline pulmonary function, (FEVy 2 60% predicted value), no history ofasthma exacerbation within 2 wk prior to study, and an absence ofconcomitant disease. B2 agonists, cromolyn, and antihistamines were withheld for 24 h prior to challenge. At the time of study, three of the subjects were on no medication, two (W.W. and E.S.) were on theophylline, and two (E.R. and J.B.) were on theophylline and prednisone. One additional volunteer subject (J.M.) was studied with normal baseline pulmonary functions and a history of intermittent attacks of bronchospasm secondary to irritant exposure. This individual demonstrated positive skin tests, but a negative aerosolized inhalational challenge with relevant allergen, and was studied after a positive methacholine challenge. Additional details regarding the challenged group are presented in Table I .
Nonchallenged asthmatics. 10 subjects were evaluated with active asthmatic disease of varying severity. Two volunteer subjects were examined with mild disease stable for 2 wk prior to study. Eight additional hospitalized subjects underwent bronchoscopy for diagnostic/therapeutic considerations. Subjects in this category had been refractory (failure to improve subjectively or regain previous baseline FEVy) to intensive treatment with high-dose steroids, bronchodialators, and respiratory therapy. Bronchoscopy in this group was performed to assess the possibility of mucus plugging of the airways as a contributing factor. A retrospective analysis of similar subjects undergoing bronchoscopy at our institution has recently been published indicating the safety of this procedure and possible therapeutic benefit (17) . The clinical histories of these patients were not suggestive ofallergen-provoked symptoms at the time of study. In the majority of cases, the cause of the relapse was not known. Concurrent sinusitis was present in patient D.S. Patients C.F., N.F., and K.C. had a suspected antecedent viral infection. In the two volunteer patients, (K.N. and M.G.E.), medications were withheld for 24 h prior to study. All remaining subjects received a high dose ofsteroids, therapeutic amounts oftheophylline, and respiratory therapy with inhaled B2 agonists. Additional relevant medications included troleandomycin (D.O.) and aspirin (N.F.). All subjects were nonsmokers with the exception of M.G. who has a 45-pack-year history. Additional details are presented in Table II .
Challenges
Aerosolized allergen. Challenges were begun with initial 1-ml doses of a 10-fold reduced wt/vol dilution of allergen from that required to elicit an immediate wheal-flare skin response. The range of allergens utilized included cat, mixed grass, Bermuda, mite, and Hormodendrum. Solutions were administered by five inhalations from a DeVilbiss Co. nebulizer (Somerset, PA) attached to a dosimeter. Responses were monitored at 10-min intervals by PFT. Serial challenges were administered with 10-fold increases (wt/vol) in allergen concentration until a reaction occurred ora 1:100 wt/vol dilution ofallergen extract was achieved. A .20% drop in FEVy, was used as criteria for a positive response.
Methacholine. Challenge was performed with an initial dose of0.625 mg/ml (1-mi inhalation) under the conditions described above. PFT were followed at 90-s time points with interval doubling ofthe dose until a positive response was achieved or a 10-mg dose was reached.
BAL and sample collection B2 agonist inhalation was administered prior to the procedure. In the challenged patients, reversal ofbronchospasm was documented with PFT to within 90% ofthe previous baseline immediately before the procedure. Oxygen was administered and bronchoscopy performed under local anesthesia. 30 ml ofsterile normal saline was injected into a lobar segment and immediately withdrawn. One to two lobes were routinely lavaged. Each sample was analyzed separately. Samples were strained through gauze to remove mucous. An aliquot of BAL fluid was reserved for cellular analysis. The remaining BAL fluid was centrifuged immediately, and supernatants were snap-frozen at -70'C until analyses were performed. Subjects were monitored during procedures with vital signs, and continuous electrocardiographic (ECG) monitoring. After bronchoscopy, pulmonary functions were repeated, and additional bronchodialator treatments were given if FEV, was .80% of baseline. In the group of challenged asthmatic patients, erythema and edema were noted in patients J.B. and G.M. The remaining subjects were thought to have essentially normal airways with minimal edema. In the nonchallenged asthmatic subjects, M.G.E., K.N., and K.C. had mild edema. The remaining subjects had diffuse erythema and edema, and in patients, E.E., D.O., C.F., A.F., M.G., and N.E., mucoid impaction of the airways was reported. Bron (25) . 5-Ml aliquots of BAL fluid supernatants were incubated with 100,000 cpm '251-HMWK (16 ng) for 1 h at 37°C in 1.5-ml plastic Eppendorftubes. The final reaction volume was adjusted to 10,ul with 0.01 M Tris, pH 7.4, at 37°C. Reactions were terminated by addition of 3 Al of 15% SDS/2% ,-mercaptoethanol followed by 3-min incubations at 100°C. Samples were separated in 9% SDS-PAGE (26) Inhibitor pretreatment ofBALfluid. BAL fluid was incubated for 10 min at room temperature with synthetic protease inhibitors prior to kininogenase activity determination. The inhibitors phenylmethylsulfonyl fluoride (PMSF, Calbiochem-Behring Corp., San Diego, CA), D-phe-Lphe-arg-Ch2CI (purchased from Calbiochem), and EDTA were employed in these experiments.
Purified antibody treatment ofBALfluid. The effect of purified antihuman prekallikrein (anti-PK) antibody (prepared in goats and shown to yield a single precipitin band in normal, but not PK-deficient human plasma) on BAL fluid kininogenase activity was assessed in concentrations known to block activity ofthe plasma kallikrein standard. Preincubation of BAL with anti-PK antibody for 10 min at room temperature was followed by the assay for kininogenase activity. Monospecific anti-HUK and monospecific anti-NE antibodies, prepared in rabbits, were assayed by the identical protocol. The anti-HUK was purified by ammonium sulfate precipitation and protein A-Sepharose chromatography, and the purified antibody was then passed over a soybean trypsin inhibitor (SBTI) column, diisofluorophosphate-treated to remove kallikrein activity, and extensively dialyzed. Preimmune sera treated in the identical fashion Rad Laboratories, Richmond, CA) (27). The nitrocellulose was dried and stored overnight in an airtight container at -20°C. The nitrocellulose was then brought to room temperature and blocked with 3% (wt/vol) nonfat powdered milk in phosphate-buffered saline, pH 7.2, for I h. Samples were probed by 90-min room temperature incubations with either purified anti-HUK (68.5 Mg/ml) in 3% milk, or immune anti-HUK sera diluted 1:500 vol/vol in 3% milk (sources and preparation of antibody described in preceding sections). Control incubations were performed under the identical conditions described with either preimmune sera or purified IgG as a probe. The nitrocellulose was washed and the primary antibody was detected by enzyme immunoassay. The nitrocellulose was incubated with affinity-purified, horseradish peroxidase-conjugated goat anti-rabbit IgG (1:1,000 dilution in 3% milk; Bio-Rad Laboratories) for 30 min at room temperature, washed, and incubated with substrate (3,3' diaminobenzidine 4 HCl, 0.01% H202, 0.1 M Tris HC1, pH 7.4) for 3-5 min at room temperature.
BAL fluid TAME esterase activity. 40-M' aliquots of BAL fluid supernatant and 10 Ml of 0.2 M Tris buffer, pH 8.0, were added to 1.5-ml Eppendorf microtubes with 10 Ml (1.5 X 10' dpm, -10' M final concentration) of [3H]TAME (Amersham Corp., Arlington Heights, IL). Tubes were placed in capped counting vials containing 10 ml of Econofluor and 50 Ml of stop solution (I vol glacial acetic acid/9 vol 0.02 TAME). After I h the reaction was terminated by shaking and tritiated methanol partitioned into Econofluor (New England Nuclear, Boston, MA). Vials were counted for 4 min in a liquid scintillation counter (Beckman Instruments, Inc., Palo Alto, CA) (28) .
BALfluid cleavage ofH-D-Val-Leu-Arg-pNA. H-D-Val-Leu-Arg-pNA (S-2266) was purchased from KabiVitrum (Stockholm, Sweden). Dilution buffer (0.05 M Tris, pH 8.0) was added to achieve appropriate concentrations of the tripeptide (200 gM). were performed to assess recovery of bradykinin at different stages of this procedure by addition of a known quantity of bradykinin prior to extraction and during incubation with BAL fluid and HMWK preceding radioimmunoassay (RIA) determinations ofkinin. Generated kinin was assayed by RIA after extraction to remove kininogen. This was performed by a modification of the method ofCarretero et al. (29) . Briefly, samples were made 80% in ethanol, incubated for 15 min at 4VC, and centrifuged at 1,200 g for 5 min. The supernatant was retained and the precipitate was washed with 100 Ml of 80% methanol. After centrifugation, the supernatants were combined and passed over a column (0.8 X 2 cm) of QAE-Sephadex A-50 equilibrated with 0.0075 M Tris/0.025% NaN3, pH 8.0. The column was eluted with this buffer until 8 ml of eluate had been collected (to ensure that the ethanol content of the eluate was low enough not to interfere with Sep-Pak [Waters Associates, Milford, MA] extraction). The eluate was then passed over a Sep-PAK cartridge, and kinin was eluted with 50% acetonitrile as previously described (1 1). This eluate was concentrated to 50 gl using a Savant speed Vac concentrator (Savant Instrument, Inc., Hicksville, NY), reconstituted to 1 ml using RIA buffer, and assayed. HPLC analysis ofkinin generated by BAL fluid. 150 Ml aliquots of HPLC-fractionated BAL fluid containing peak kininogenase activity were incubated with 3 Mg of purified HMWK for 5.5 h in the presence of buffer (40 mM EDTA 0.01 M Tris, pH 7.4) at 370C. Reactions were terminated by addition of buffer to final volumes of0.5 ml and freezing at -700C. Generated kinin was quantified by RIA as described in the preceding section. The resultant kinin-containing material was prepared for analysis and separated by published methods (I 1).
Statistical analyses
All data was entered and statistical analyses were performed by Clinfo Systems at Scripps Clinic and Research Foundation.
Results
Kininogenase activity in BAL fluids. BAL fluids from 17 asthmatic subjects who either responded to allergen challenge or had symptoms of active asthma were examined for the presence of kininogenase activity. As determined by the ability to cleave radiolabeled substrate ('25I-HMWK), kininogenase activity was present in 22 of 24 samples. In contrast, BAL fluid obtained from the quiescent asthmatic subject after a negative allergen and a positive methacholine challenge failed to cleave kininogen. Similarly, in the nonasthmatic normal controls, six of seven samples lacked enzymatic activity. Results are displayed in Table  III . The major cleavage product in all cases examined appeared at an apparent molecular weight of 65,000. Additional cleavage products were detected at 45,000 and 80,000 mol wt.
Representative examples of BAL fluid cleavage profiles of 1251-HMWK appear in Fig. 1 The finding of enzymatic activity in nonchallenged asthmatics would indicate that an anaphylactic stimulus was not a prerequisite for its presence and/or activation. The study did not address whether an anaphylactic stimulus could augment baseline levels of the enzyme. Characterization ofkininogenase activity. In order to define further the properties ofthe BAL fluid kininogenase, the inhibitor profile was determined. Kininogenase activity was abrogated by preincubation with PMSF (l0-4 M) but was not affected by 40 mM EDTA, an inhibitor of metalloproteases. These results indicate that the BAL fluid kininogenase(s) could be classified as a serine proteases. Additionally, the kininogenase activity was significantly inhibited by phe-phe-arg-CH2Cl in the range of 10-2 to lO-' M concentrations (Fig. 2) , providing partial evidence that the BAL kininogenase(s) could be grouped with plasma and tissue kallikreins. Phe-phe-arg-CH2Cl has been previously shown to be a selective inhibitor of these enzymes, though of greater potency for plasma vs. the tissue kallikreins (30) .
The '25I-HMWK cleavage pattern produced by asthmatic BAL fluid was next compared with those produced by other proteases (plasma kallikrein, urinary kallikrein, mast cell tryptase, and NE). As demonstrated in Fig. 3 , the dominant cleavage pattern of BAL luid (65,000 mol wt) was homologous to that of urinary kallikrein. Plasma kallikrein produced a prominent 45,000-mol wt fragment in addition to the 65,000-mol wt cleavage fragment. Mast cell tryptase produced a 65,000-mol wt fragment; however, its dominant cleavage product was at 80,000 mol wt. NE resulted in multiple breakdown products.
Analysis for TAME esterase activity was performed on selected supernatants from asthmatic subjects. The ability to cleave _~hlI 1 lOK Figure 1 17 asthmatics contained kininogenase activity in contrast to a single control sample. Labeling designates the apparent molecular weight of the fragments. The 65,000-mol wt fragment was the major cleavage product in all cases. The first lane contains "251-HMWK incubated with control buffer. The cleavage profiles are displayed in the following three lanes: (1) 65,000 mol wt with a virtual absence of additional cleavage products, (2) 65,000-and 45,000-mol wt fragments, and (3) 65,000 with 45,000 and 80,000-mol wt fragments. K, molecular weight in thousands. The molecular weight ofthe kininogenase activity contained in BAL fluid was determined by gel filtration using HPLC. Fig.  5 shows the BAL fluid protein elution profile and corresponding kininogenase activity of the HPLC fractions. The peak kininogenase activity was isolated in the range of 20,000-34,000 mol wt. In these experiments, assays for kininogenase activity employed 30-II aliquots of column fractions. The elution times of known molecular weight standards (depicted by the dotted line) were utilized to determine the representative molecular weight ranges ofthe column fractions. Purified urinary kallikrein under the identical conditions was found to elute at -34,000 mol wt. Mast cell tryptase was isolated at -140,000 mol wt. As displayed in Fig. 6 , amidolytic activity for the synthetic substrate Val-LeuArg-pNA was found to coelute with the peak cleavage activity for '25I-HMWK.
The antigenic identity of the asthmatic BAL fluid kininogenase was investigated by assessing the effects of purified antiprotease antibodies (Fig. 7) . Preincubation with anti-NE antibody failed to significantly effect BAL fluid kininogenase activity, as expected from the nonhomologous appearance of the NE cleavage profile compared with that of BAL fluid. In the majority ofinstances, anti-PK preincubation also failed to effect kininogenase activity in asthmatic BAL fluid, although partial blocking of activity did occur in six samples. In Effect of anti-PK and anti-NE on BAL fluid kininogenase activity. No significant effect on BAL fluid kininogenase activity was found after preincubation with anti-NE in titrations determined to block the activity of purified standard NE. In the majority of cases, anti-PK also failed to inhibit 1251I-HMWK cleavage by BAL in titrations sufficient to block purified plasma kallikrein control (PLAS KAL). Evidence of plasma kallikrien activity was detected in six samples (described in text). Abbreviations: a, anti-; K, molecular weight in thousands.
noblotting crude BAL fluid for tissue kallikrein is displayed in Fig. 9 . In the crude lavage, three tissue kallikrein bands were visualized at 52,000, 42,000, and 28,000 mol wt. Purified HUK standard by this technique immunoblotted at 42,000 mol wt.
Immunoblotting of concentrated individual column fractions appears in Fig. 10 . In addition to the 52,000-, 42,000-, and 28,000-mol wt densities, a faintly staining high molecular weight form is also visualized. Whether these forms reflect the presence of bound inhibitor or processing of the enzyme is not yet clear. Peak kininogenase activity both by cleavage of 1251-HMWK and Val-Leu-Arg-pNA was associated with the 42,000-and 28,000-mol wt forms.
Cellular analysis and BAL fluid recovery. Mean total cell counts per milliliter for challenge-positive asthmatics were 1.42±0.4 X 10'. Nonchallenged asthmatics averaged 5.7±1.4 X 10'. Normals averaged 10.9±5.3 X 10'. Cell counts in the asthmatic groups were felt to be artifactually low due to the high mucus content in BAL fluid and cell loss during mucus filtering procedures.
Cytocentrifuge preparations showed >88% alveolar macrophages in the normal controls. In the asthmatic subjects, leu- Mean values for recovery of the 30-ml BAL fluid lavage were as follows: in asthmatics responding to allergen challenge, 6 .8+1.1 ml; in nonchallenged asthmatics, 9.8±1.5 ml. In the methacholine-challenged subject, 5.2 and 12 ml were recovered. Normals showed an approximate 50% recovery.
Determination offree kinin in BAL fluids. Levels of immunoreactive kinin in the asthmatic BAL fluid were found to be elevated in all kininogenase-containing samples. The percentage of 125I-HMWK label appearing in the 65,000-mol wt fragment after incubation with BAL fluid was found to be highly correlated with the amount of kinin detected by RIA (P value 0.0017 by linear regression). Mean values for immunoreactive kinin were as follows: asthmatics responding to allergen challenge, 376±98 pg/ml in eight kininogenase-containing samples vs. 128 pg/ml in the two inactive samples; in nonchallenged asthmatics, 1,267±328 pg/ml was present (n = 11); and in normals 144±51 pg/ml (n = 4). In the two kininogenase-negative samples from J.M. after methacholine challenge, 60 and 180 pg/ml of kinin was detected.
Kinin generation by BAL fluids. The ability of the kininogenase to produce kinin from purified HMWK substrate was verified in vitro. Fractions eluted from HPLC gel filtration columns containing the peak kininogenase activity generated 2,174 52K-42K-28K-30 40 42 45 47 50 60 BAL FLUID HPLC FRACTION Figure 10 . Detection of tissue kallikrein in HPLC fractionated BAL fluid. BAL fluid was subjected to HPLC gel filtration as described in text. Individual column fractions were concentrated, separated in 10% SDS-PAGE, and transferred to nitrocellulose. The samples were probed for tissue kallikrein and detected as described in the preceeding figure. In addition to the 52,000-, 42,000-, and 28,000-mol wt densities, a faintly staining higher molecular weight form was also visualized. Peak kininogenase activity both for '25I-HMWK and Val-LeuArg-pNA was associated with the 42,000-and 28,000-mol wt forms. K, molecular weight in thousands. pg ofimmunoreactive kinin. A control incubation ofthe column fractions with buffer alone contained only 28 pg of kinin. Unfractionated BAL supernatant containing kininogenase activity (cleavage of '25I-HMWK) was also capable of generating significant amounts of kinin. Mean kinin generation in six challenged asthmatics was 723±249 pg/ml vs. a buffer control mean of 37±4 pg/ml, and in 11 nonchallenged asthmatics, the mean kinin generation was 986±186 pg/ml vs. buffer control mean 31±6 pg/ml.
The recovery of bradykinin in these procedures was tested. 91-99% ofpurified bradykinin added to buffer prior to extraction for RIA was recovered, whereas only 39% ofexogenous purified bradykinin incubated with crude supernatant for 1 h and subsequently extracted for RIA was recovered. This loss during incubation may represent the activity of a competing kininase present in the BAL fluids. Of note was that addition of EDTA during the incubations was of little protective effect. Thus the values measured for kinin generated by addition of the BAL fluid to HMWK may represent somewhat less than half of the true value.
HPLC analysis ofgenerated kinin. The type of kinin generated during incubations of HPLC-fractionated BAL fluid kininogenase and purified HMWK was determined. Total kinin generated was quantified by RIA in three separate kininogen incubations with fractionated BAL fluid (E.S.[A] 6,216 pg/ml, E.E. 6,855 pg/ml, and D.O. 5,555 pg/ml). The kinin was then extracted and applied to reverse-phase HPLC columns. Samples E.S.(A) and E.E. were pooled and D.O. was analyzed separately.
Retention times ofkinin generated by BAL fluid were compared with purified standards. Results are displayed in Fig. 11 . The predominant biologic product in all cases was lysylbradykinin, the characteristic cleavage product ofthe tissue kallikreins. RETENTION TIME (min) Figure 11 . HPLC analysis of generated kinin. Aliquots of HPLC fractions containing peak BAL fluid kininogenase activity were incubated with purified HMWK. Generated kinin was quantified by RIA. Results of HPLC analysis of generated immunoreactive kinin. In each case, the retention time for >90% of the BAL generated kinin corresponded with the lysylbradykinin standard.
Discussion
We have identified the presence of kininogenase activity in the BAL fluid ofasthmatic subjects. 24 lavage samples were collected from 17 subjects with symptomatic asthma or provoked responses to aerosolized allergen and subjected to immunochemical analysis. In 22 of 24 samples, active kininogenase was detected by the ability to cleave radiolabeled purified kininogen. In contrast, six ofseven normal controls lacked evidence ofkininogenase activity. Increased levels ofimmunoreactive kinin were found to parallel the presence of kininogenase activity in BAL fluids. The BAL fluid kininogenase activity produced a predominant cleavage fragment of 65,000 apparent molecular weight when incubated with '25I-HMWK. This was homologous with the pattern seen in incubations of purified tissue kallikrein standard (HUK) with the radiolabeled kininogen substrate. Similar results for cleavage for HMWK by purified tissue kallikrein were obtained by Mori et al. (31) utilizing a human salivary kallikrein preparation. In these studies, HMWK was cleaved into apparent molecular weight fragments of 62,000 and 56,000, with documented release ofkinin. Our technique for detecting kininogenase activity in BAL fluid employing a reduced gel size (75 X 50 mm) and radiolabeled substrate may not have resolved a small molecular weight difference in cleavage products from comigrating fragments. The chloramine-T method for labeling HMWK would also be expected to provide a higher intensity band for fragments derived from the heavy chain owing to the greater number of tyrosine residues (32), and therefore, pose greater difficulty in detecting light chain-derived fragments.
Analysis of the physical properties, immunologic reactivity, and function indicated that the major enzyme in the BAL fluids of asthmatic subjects was a tissue kallikrein. The synthetic inhibitor profile of the BAL fluid kininogenase activity was consistent with that of kallikrein-like serine proteinases. The ability to cleave 25I-HMWK was abrogated by preincubation with PMSF and significantly attenuated by phe-phe-arg-CH2Cl, the chloromethyl ketone inhibitor of tissue and plasma kallikreins (30 Evidence that plasma kallikrein was contained in some BAL fluids was provided by the partial inhibition of 125I-HMWK cleavage by anti-PK preincubation. The presence ofboth 65,000-and 45,000-mol wt fragments in several samples would also be compatible with the presence of this enzyme. Cleavage profiles of this type under similar conditions have been previously reported with purified plasma kallikrein (24). A potential mechanism for the direct local activation of prekallikrein in the lung may be inferred from in vitro studies on human lung tissue (36) . In these experiments, after anaphylactic challenge, lung prekallikrein activator (LPKA), was released, capable of generating active kallikrein. This putative mast cell/basophil product could theoretically be released under other, non-IgE-mediated circumstances relevant to asthmatic provocations (i.e., hyperosmolar, reference 37), or as a consequence of the presence of other inflammatory mediators (i.e., kinin). Small amounts of plasma-derived Hageman factor may also be present in the bronchoalveolar spaces during inflammatory reactions, providing an alternative means of prekallikrein activation through the contact system cascade (38) .
To our knowledge, tissue and plasma kallikrein have not been previously identified in vivo from human lung. In vitro studies on human basophils (39, 40) and lung tissue (41) have detected the presence ofkininogenase(s) after anaphylactic challenge. The kininogenase activity(s) in each case is distinguished from the BAL fluid activity by high molecular weight. Similarly, although the IgE-mediated release ofa kininogenase from human lung mast cells has been reported, this activity can also be distinguished from the tissue kallikrein in BAL fluids on the basis of both molecular weight (145,000) and the fact that the mast cell kininogenase generated kinin optimally at pH 5.5 (42). The properties of this mast cell kininogenase have led to the suggestion that it may be identical to tryptase, the major neutral protease from human lung mast cells. The role of tryptase in kinin generation remains to be clarified however, with a separate report indicating that this enzyme is not capable of generating kinin from natural substrate (43) . Although not specifically addressed in these experiments, mast cell tryptase may have accounted for the generation of the 80,000-mol wt fragment seen in a single sample of asthmatic BAL fluid.
The detection of tissue kallikrein activity in both the allergen challenged and nonprovoked asthmatics would imply that alternative (non-IgE-mediated) mechanisms are at least in part operative in its release and/or activation. Its presence may reflect what is the common denominator of persistent asthma, local inflammation, for which anaphylactic stimuli are but one initiating/amplifying factor, the relative contribution ofwhich was not addressed in the current study. If this hypothesis is correct, it would be unlikely that kininogenase activity would be limited to asthmatics and not found in other types of local pulmonary inflammatory events. To clarify this possibility, we have recently studied two individuals with active pulmonary inflammation (bronchitis and pneumonitis), both of whom lacked asthmatic or atopic disease. Kininogenase activity(s) was detected in BAL fluid supernatants with generation of a 65,000-mol wt fragment from 125I-HMWK, associated with elevated amounts of immunoreactive kinin. Tissue kallikrein was present by immunoblotting with anti-HUK antibody. The predominant type of kininogenase activity in these subjects remains to be established. The anticipated consequence of kinin generation in nonasthmatic individuals would include promotion of edema and potential generation and/or release of additional inflammatory mediators (leukotrienes, platelet-activating factor, and mast cell products). Lacking in these responses would be the bronchospasticity unique to the asthmatic group.
In summary, this study provides the first demonstration of kininogenase activity and elevated amounts ofkinin in the BAL fluid of asthmatic subjects. The predominant kininogenase possessed the structural, functional, and antigenic characteristics of a tissue kallikrein. In a minority of subjects, plasma kallikrein was also detected. The potential importance of kinin-generating activity in asthma stems both from the direct effects of kinin and its interrelationship with additional putative preformed and generated mediators. The presence ofthe tissue and plasma kallikrein activities in the bronchoalveolar spaces ofasthmatic subjects could, via kinin generation, participate in the cascade of events leading to clinically recognized asthma.
